Health Technology Assessment

The 2016 HTAi Annual Meeting was held in Tokyo, Japan, 10-14 May 2016. The focus of the meeting was Informing Health Care Decisions with Values and Evidence. This post contains presentations given by the OHE team.

ISPOR’s 21st Annual International Meeting is scheduled for 20-25th May 2016 in Washington DC. Several members of the OHE team will be attending and disseminating important research.

Martina Garau presented at the last ISPOR Italy Chapter – Rome conference on the topic of economic gains produced by health interventions.

Work by Sarah Karlsberg Schaffer (OHE), Jon Sussex (RAND Europe), Dyfrig Hughes (Bangor University) and Nancy Devlin (OHE) has recently been published in BMC Health Services Research.

OHE publishes new Consulting Report on shaping the research agenda to estimate relevant cost-effectiveness thresholds for Health Technology Assessment decision making.

The blog provides links to slide sets for presentations relating to going ‘beyond QALYs’ when valuing health care interventions, managed entry agreements within the UK pharmaceutical landscape, new business models for antibiotics, and economics of the market for medicines

Dr Amanda Adler, Chair of NICE Appraisal Committee B and Consultant Physician, will present an OHE Seminar on 19 April 2016.

Two newly published OHE Research Papers report the methods and findings of the ‘EQ-5D-5L value set for England’ study.

Health interventions can produce economic gains for patients and national economies. In practice, however, the health-wealth link is rarely considered.

An analysis in the trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015 has just been published in an OHE Consulting Report. This report was initiated and funded by Pfizer Ltd.
 
The report assesses...

Pages

Subscribe to RSS - Health Technology Assessment